RT Journal Article
SR Electronic
T1 A Case of <sup>177</sup>Lu-DOTATATE Therapy Without the Use of Antiemetics
JF Journal of Nuclear Medicine Technology
JO J. Nucl. Med. Technol.
FD Society of Nuclear Medicine
SP 354
OP 355
DO 10.2967/jnmt.121.261996
VO 49
IS 4
A1 Justin G. Peacock
A1 Brendan O’Sullivan
A1 Michael R. Povlow
YR 2021
UL http://tech.snmjournals.org/content/49/4/354.abstract
AB Recommended 177Lu-DOTATATE treatment regimens involve prophylaxis with antiemetics to counteract the emetogenic properties of the nephroprotective amino acid solution infusion. We describe a 58-y-old woman treated with 177Lu-DOTATATE for metastatic small-bowel carcinoid, who was allergic to many classes of antiemetics. Therefore, she was treated with 177Lu-DOTATATE without antiemetic prophylaxis. She tolerated the compounded amino acid infusion of lysine and arginine, followed by 177Lu-DOTATATE, without significant nausea or any vomiting. We hypothesize that aggressive antiemetic prophylaxis may not be necessary if a 177Lu-DOTATATE patient receives compounded lysine/arginine amino acid solutions. The omission would decrease overall health-care costs and limit possible medication side effects.